SPPL2B

SPPL2b is a GXGD-type aspartyl intramembrane protease that mediates regulated intramembrane proteolysis of type II-oriented transmembrane substrates and tail-anchored SNARE proteins, linking membrane proteolysis to immune signaling and membrane protein homeostasis (PMID:16829952, PMID:36047592). It is delivered through the secretory pathway to endosomal/lysosomal vesicles and the plasma membrane—distinct from the ER-restricted family members SPP and SPPL3—and its catalytic activity depends on the conserved C-terminal active-site aspartate within the GXGD motif, which is required for its in vivo function (PMID:15998642, PMID:16829952). SPPL2b cleaves TNFα to release an intracellular domain that drives IL-12 expression in activated dendritic cells, and it processes Bri2/Itm2b only after prior ectodomain shedding by ADAM10, generating an intracellular domain and a secreted C-terminal peptide (PMID:16829952, PMID:17965014). Efficient cleavage is governed by substrate-intrinsic determinants: shed ectodomain length, juxtamembrane and intracellular sequences, and the α-helical content of the transmembrane domain, where a single conserved intramembrane glycine modulates both TMD secondary structure and processing efficiency (PMID:19114711, PMID:22194595). Beyond type II substrates, SPPL2b processes the SNARE proteins VAMP1–4, controlling their cellular levels in a tissue-dependent manner in vivo (PMID:36047592). The protease has been reconstituted in vitro with purified components, recapitulating cellular cleavage sites and TMD turnover and enabling characterization of lipid and cholesterol dependence and a selective small-molecule inhibitor (PMID:38636792).

1. 2005 High

   Establishing where SPPL2b acts and whether its predicted catalytic residue is functionally required addressed whether it is a genuine, compartment-specific protease.

   Evidence Subcellular localization in cultured cells plus active-site (GXGD D/A) mutagenesis and antisense knockdown phenocopy in zebrafish

   PMID:15998642

   Open questions at the time

   • The physiological substrate underlying the zebrafish phenotype was not defined
   • No direct biochemical demonstration of proteolysis at this stage
2. 2006 High

   Identifying TNFα as a substrate and linking the released intracellular domain to cytokine output showed SPPL2b is a functional protease coupled to immune signaling.

   Evidence Cellular co-expression cleavage assays with localization studies and IL-12 readout in human dendritic cells

   PMID:16829952

   Open questions at the time

   • Did not establish the requirement for prior ectodomain shedding
   • In vivo relevance of TNFα ICD signaling not tested
3. 2007 High

   Systematic comparison across the SPP/SPPL family defined SPPL2a/b as selective for Bri2 and revealed a sequential shedding-then-intramembrane-cleavage mechanism.

   Evidence Co-expression of all family members and loss-of-function variants with Bri2; Western blot of cleavage products

   PMID:17965014

   Open questions at the time

   • Did not resolve which substrate sequence features dictate selectivity
   • Functional consequences of Bri2 ICD release not addressed
4. 2008 High

   Defining the substrate determinants of Bri2 processing clarified why shedding alone is insufficient and explained substrate selectivity within close homologues.

   Evidence Serial deletions and domain swapping with Bri3 as negative control in cellular SPPL2b assays

   PMID:19114711

   Open questions at the time

   • The structural basis for sequence preference was not resolved
   • Mechanism of TMD recognition by the protease not defined
5. 2011 High

   Connecting TMD secondary structure to cleavage efficiency provided a biophysical principle governing intramembrane proteolysis by SPPL2b.

   Evidence Site-directed mutagenesis of Bri2 TMD with circular dichroism and cellular cleavage assays

   PMID:22194595

   Open questions at the time

   • No structure of the protease–substrate complex
   • Whether the same α-helical principle governs other substrates untested at the time
6. 2022 High

   Identifying VAMP1–4 as substrates expanded SPPL2b's role beyond type II proteins to control of SNARE-mediated membrane fusion regulators in vivo.

   Evidence SNARE co-expression screen, inhibition in cell lines, and VAMP level analysis in SPPL2a/b double-knockout mice

   PMID:36047592

   Open questions at the time

   • Functional consequences of VAMP accumulation for membrane fusion not fully resolved
   • Relative contribution of SPPL2a versus SPPL2b not separated in dKO
7. 2024 High

   Reconstituting SPPL2b activity with purified components established a defined biochemical system recapitulating cellular cleavage and enabling inhibitor and lipid-dependence studies.

   Evidence In vitro protease assay with purified SPPL2b and TNFα, lipid/cholesterol titration, and characterization of the inhibitor SPL-707

   PMID:38636792

   Open questions at the time

   • No high-resolution structure derived from the reconstituted system
   • Lipid regulation in native membranes versus detergent not fully equated

• How SPPL2b substrate recognition is structurally encoded and how its proteolysis of distinct substrate classes is integrated into physiology remain open.
• No experimentally determined structure of SPPL2b or its protease–substrate complex
• Physiological roles of SNARE versus type II substrate processing not disentangled in vivo